November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Guru Sonpavde: Meta-analysis of adjuvant PD1/L1 inhibitor immunotherapy in MIBC
Nov 5, 2024, 17:59

Guru Sonpavde: Meta-analysis of adjuvant PD1/L1 inhibitor immunotherapy in MIBC

Guru Sonpavde, Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida, shared a post on LinkedIn about his recent paper published in Urologic Oncology: Seminars and Original Investigations:

“Meta-analysis of adjuvant PD1/L1 inhibitor immunotherapy Phase 3 clinical trials (2,220 patients) demonstrated significantly improved disease-free survival (DFS) for PD1/L1 inhibitor therapy in the

  1. intention-to-treat cohorts (HR 0.76, 95% CI 0.65-0.90),
  2. negative PD-L1 expression (HR 0.76, 95% CI 0.64-0.90),
  3. those who received prior NAC (HR 0.69, 95% CI 0.52-0.91),
  4. lower tract (HR 0.71, 95% CI 0.55-0.92) but not upper tract disease (HR 1.21, 95% CI 0.87-1.68).

Caveats of meta-analysis apply- coauthoring from AdventHealth Central Florida Cancer Institute in a study led by Raj Satkunasivam.”

“Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials”

Authors: Laura Oscar-Thompson, Carlos Riveros, Guru Sonpavde, Andrea Apolo, Aly-Khan Lalani, Christopher Wallis, Raj Satkunasivam.

Guru Sonpavde: Meta-analysis of adjuvant PD1/L1 inhibitor immunotherapy in MIBC

More posts featuring Guru Sonpavde.

Dr. Guru Sonpavde is the Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida and the Chair of Bladder Cancer Research.

He is also a Professor of Medicine at the University of Central Florida. His primary focus is drug development, leading innovative clinical trials on novel immunotherapies and targeted therapies for genitourinary cancers, especially bladder cancer, along with prostate, kidney, penile, and testicular cancers.